PARProceedings of Anticancer Research2208-35452208-3553Bio-Byword Scientific Publishing Pty. Ltd.10.26689/par.v9i4.11505ArticleCase Study and Literature Review on Diagnosis and Treatment of Advanced Metastasis of Tumor with Unknown Primary Originhttps://artdesignp.com/journal/PAR/9/4/10.26689/par.v9i4.11505DongLeting,YueShi,GaoYungui,YinYaqi,HuangShengli2025942025-08-06Primary of Unknown Origin Cancer (CUP) is a metastatic tumor whose origin remains undetermined. The reason for this ambiguity in identifying the primary site remains unclear, possibly due to the tumor being too small or growing too slowly, or because the immune system has destroyed the tiny primary lesion. Most CUP patients receive only localized treatment or empirical systemic chemotherapy, leading to poor prognosis and shorter average overall survival. There is currently insufficient evidence-based medical support for the diagnosis and treatment of CUP. This study retrospectively analyzed clinical characteristics, diagnostic methods, treatment approaches, and prognostic outcomes of newly diagnosed CUP patients treated in our department. The findings aim to provide clinical guidance for diagnosis and treatment of CUP, with the goal of reducing diagnostic delays and improving patient outcomes.

Rassy E, Pavlidis N, 2019, The Currently Declining Incidence of Cancer of Unknown Primary. Cancer Epidemiol, 61: 139–141.

Rassy E, Pavlidis N, 2020, Progress in Refining the Clinical Management of Cancer of Unknown Primary in the Molecular Era. Nat Rev Clin Oncol, 17(9): 541–554.

Rassy E, Assi T, Pavlidis N, 2020, Exploring the Biological Hallmarks of Cancer of Unknown Primary: Where Do We Stand Today? Br J Cancer, 122(8): 1124–1132.

Rassy E, Parent P, Lefort F, et al., 2020, New Rising Entities in Cancer of Unknown Primary: Is There a Real Therapeutic Benefit? Crit Rev Oncol Hematol, 147: 102882.

Clynick B, Dessauvagie B, Sterrett G, et al., 2018, Genetic Characterisation of Molecular Targets in Carcinoma of Unknown Primary. Journal of Translational Medicine, 16(1): 1–10.

Fizazi K, Greco M, et al., 2015, Cancers of Unknown Primary Site: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 26(S5): V133–V138.

Gaspà L, Díaz L, Pérez S, 2025, Cancer of Unknown Primary: Diagnosis, Treatment and Technological Advances. Medicina Clinica, 165(5): 107118.

Spurgeon L, Mitchell C, Cook N, et al., 2025, Cancer of Unknown Primary: The Hunt for Its Elusive Tissue-of-Origin – Is It Time to Call Off the Search? British Journal of Cancer, (prepublish): 1–10.

Boon I, Lim J, Yong A, et al., 2025, Precision Medicine and Genomics in Cancer of Unknown Primary. Clinical Oncology, 43: 103854–103854.

Lazzaro A, Srinivasan M, Assi H, 2025, Cancer of Unknown Primary: A Case Report on the Recognition of Its Clinical Entity and Standard of Care Management. Cureus, 17(6): e86451–e86451.

Rebello J, Posner A, Dong R, et al., 2025, Whole Genome Sequencing Improves Tissue-of-Origin Diagnosis and Treatment Options for Cancer of Unknown Primary. Nature Communications, 16(1): 4422–4422.